Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MY-586 Nasal Spray Safety Study in Healthy Subjects
NCT05977101Phase 1Unknown
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing MY-586 with Placebo (2 arms). Primary endpoints: Vital signs, Laboratory tests and 2 more. Status: unknown.
02
Drugs
covid-19 antibody nasal spray
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05977101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05977101.